- Home
- NIVF vs SLRX Comparison
NIVF vs SLRX Comparison
Compare NIVF & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- SLRX
- Stock Information
- Founded
- NIVF 2011
- SLRX N/A
- Country
- NIVF Thailand
- SLRX United States
- Employees
- NIVF N/A
- SLRX N/A
- Industry
- NIVF
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- SLRX Health Care
- Exchange
- NIVF NYSE
- SLRX Nasdaq
- Market Cap
- NIVF 2.1M
- SLRX 1.8M
- IPO Year
- NIVF N/A
- SLRX N/A
- Fundamental
- Price
- NIVF $2.20
- SLRX $0.72
- Analyst Decision
- NIVF
- SLRX
- Analyst Count
- NIVF 0
- SLRX 0
- Target Price
- NIVF N/A
- SLRX N/A
- AVG Volume (30 Days)
- NIVF 7.7M
- SLRX 23.3K
- Earning Date
- NIVF 01-01-0001
- SLRX 05-14-2025
- Dividend Yield
- NIVF N/A
- SLRX N/A
- EPS Growth
- NIVF N/A
- SLRX N/A
- EPS
- NIVF N/A
- SLRX N/A
- Revenue
- NIVF $5,433,375.00
- SLRX N/A
- Revenue This Year
- NIVF N/A
- SLRX N/A
- Revenue Next Year
- NIVF N/A
- SLRX N/A
- P/E Ratio
- NIVF N/A
- SLRX N/A
- Revenue Growth
- NIVF 5.79
- SLRX N/A
- 52 Week Low
- NIVF $1.68
- SLRX $0.45
- 52 Week High
- NIVF $656.00
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- NIVF 41.58
- SLRX 41.78
- Support Level
- NIVF $1.68
- SLRX $0.68
- Resistance Level
- NIVF $6.13
- SLRX $0.80
- Average True Range (ATR)
- NIVF 0.74
- SLRX 0.04
- MACD
- NIVF 0.10
- SLRX -0.01
- Stochastic Oscillator
- NIVF 11.69
- SLRX 8.93
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.